ArticleIndian pediatrics2026
Liver Fibrosis Screening in Childhood Acute Lymphoblastic Leukemia Survivors by Transient Elastography: A Case-Control Study.
Article in Indian pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Transient Elastography in Survivorship Care of Childhood ALL: Promise, but not yet a Practice Standard.Indian pediatrics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesClinical and biochemical screening is recommended to monitor hepatobiliary late-effects in childhood acute lymphoblastic leukemia survivors (cALLs). Transient elastography (TE) noninvasively evaluates liver fibrosis by measuring liver stiffness (LSM) with good sensitivity. We screened cALLs for high-LSM using TE, comparing them to controls and evaluated risk factors for high-LSM.
methodsThis case-control study included cALLs who were under 18 years at diagnosis, had completed therapy between 2016 and 2023, and were at least 6-months post-completion of therapy. This study also included 50 age- and sex-matched controls. TE (Fibroscan®) was used for LSM, with cutoff ≥ 5.1 kPa for high-LSM indicating fibrosis, and for controlled attenuation parameter (CAP), with cutoff > 248 dB/m for steatosis.
resultsFifty-eight cALLs with mean (SD) age of 136.58 (58) months at enrollment were analyzed after mean (SD) duration of 27 (8) months post-completion of therapy. High-LSM was observed in 22/58 (37.9%) of cases. The number of children with high-LSM in cALLs (22/58) compared to control group (8/50) was significantly higher (P = 0.011). In univariate analysis, age at diagnosis ≥ 5 years, bilirubin > 1 mg/dl, and alanine transaminase (ALT) ≥ 40 U/L, while in multivariate analysis ALT ≥ 40 U/L, were found to be associated with high-LSM. Mean (SD) CAP measurement in cALLs was 192 (56) dB/m. Steatosis was seen in 11/58 (18.9%) cases. CAP had a positive correlation with serum triglycerides and cholesterol levels, and a negative correlation with adiponectin levels.
conclusionWe report a high prevalence of high-LSM (≥ 5.1 kPa) among cALLs, which indicates liver fibrosis. ALT ≥ 40 U/L was a significant predictor of hepatic fibrosis in cALLs. TE is a useful tool for evaluating hepatobiliary late-effects in cALLS.
Indexed as
Identifiers
41989725What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.